ALK Taps Internal Executive to Lead Global R&D After Seven-Month Vacancy
Event summary
- Jacob Glenting appointed EVP and head of Global R&D at ALK, effective September 1, 2026, filling a role vacant since February 2026.
- Glenting brings 25 years of pharmaceutical experience, a PhD in vaccine development, and prior leadership in ALK’s commercial operations and strategic partnerships.
- ALK’s Executive Leadership Team now includes Glenting, with a focus on advancing the Allergy+ strategy through innovation and partnerships.
- Glenting’s background includes key roles in ALK’s partnerships with Torii (now Shionogi), Abbott, GenSci, and the licensing agreement for neffy® with ARS.
The big picture
ALK’s appointment of Jacob Glenting as head of Global R&D underscores its commitment to strengthening its allergy therapy portfolio through internal expertise and external collaborations. The move comes amid a broader industry trend of pharmaceutical companies leveraging cross-functional leadership to drive innovation and market expansion. Glenting’s dual background in science and commercial strategy positions ALK to navigate the competitive landscape of allergy treatments, particularly in pediatric and anaphylaxis markets.
What we're watching
- Pipeline Expansion
- How Glenting’s leadership will accelerate ALK’s pipeline development and balance core-business growth with adjacent therapy areas.
- Partnership Dynamics
- Whether ALK can sustain and expand its strategic partnerships to drive innovation and commercial success.
- Execution Risk
- The pace at which Glenting can integrate scientific rigor with commercial strategy to deliver patient and prescriber benefits.
Related topics